New cancer drugs can also prevent cat allergies

Cancer patients who are allergic to cats or arowanas have reduced the allergic reaction by 80-90% in a week thanks to a new cancer treatment.

According to a recent study, there is a cancer drug that can significantly reduce a person's allergies.
Specifically, Northwestern University researchers have discovered a new cancer drug that replaces extremely toxic chemotherapy drugs for patients with chronic lymphocytic leukemia and cell carcinoma. capillary.

And in a small pilot study, 2 out of 35 patients were treated with ibrutinib because of cancer with allergies. Then, check the allergy status of the patient when taking ibrutinib for one to two months of treatment. The team found that cancer patients who are allergic to cats or arowanas have reduced skin allergy symptoms by 80-90% in a week and then allergies are completely corrected. lasts up to two months after treatment with ibrutinib.

Dr. Bruce Bochner, professor of medicine at Feinberg School of Medicine, Northwestern University, said: "It almost eliminated the skin allergic reactions as well as the allergic reactions of blood cells."

Bochner said the new anticancer drug was well tolerated in the body, then prevented a protein inside a cell called Tyrosine Kinase that plays an important role in B-cell activation, stimulating growth. Growth, development, biological activation of mast cells and bazophil. Previously, mast cells and baseophil were known to be responsible for the body's allergic reactions.

Dr. Bochner added that a further problem with food allergies: ' I don't know if there is a similar drug that will help patients resist peanut, butter, and bread allergies. But we believe we will use the approach in this experiment to study, learn how to help prevent allergies from food on patients '.

Currently, research is continuing to expand on whether this new drug test will help cancer patients fight food allergies and at the same time examine the experiments, how the reaction on the skin correlates with the dose, Frequency of use of iburtinib drugs.

This study has just been published in the Journal of Immunology and Clinical Allergy.